Condition

Atypical Ductal Breast Hyperplasia

ClinicalTrials.gov condition label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 5 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials5
Recruiting0
Common interventions13
Lead sponsors shown5
Advertisement

Clinical trials

5 shown
Metformin Hydrochloride in Preventing Breast Cancer in Patients With Atypical Hyperplasia or In Situ Breast CancerNCT01905046 · 2015-11-23
ACTIVE_NOT_RECRUITING
Group-Based Lifestyle Intervention in Measuring Biomarker Levels in Participants at High Risk for Breast CancerNCT01874184 · 2013-10-01
COMPLETED
Pilot Study of Curcumin for Women With Obesity and High Risk for Breast CancerNCT01975363 · 2013-06-01
COMPLETED
A Phase I Prevention Study of Atorvastatin in Women at Increased Risk for Breast CancerNCT00637481 · 2008-03-01
COMPLETED
Breast Cancer Chemoprevention by SOM230, an IGF-I Action Inhibitor: A Proof of Principle TrialNCT01372644 · 2007-11-01
COMPLETED

Trial status mix

COMPLETED4
ACTIVE_NOT_RECRUITING1

Phase mix

NA2
PHASE12
PHASE31

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.